Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure

Research output: Contribution to journalJournal articleResearch

  1. Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comprehensive Physiological Modeling Provides Novel Insights Into Heart Failure With Preserved Ejection Fraction Physiology

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as "bridge to recovery" may be warranted in similar patients.
Original languageEnglish
JournalCongestive Heart Failure
Volume18
Issue number5
Pages (from-to)291-4
Number of pages4
ISSN1527-5299
DOIs
Publication statusPublished - 2012

ID: 36843516